Icon
+91 94997 68112
Login Register

MAVYRET - (100MG;40MG ; Tablet)

GLECAPREVIR; PIBRENTASVIR Abbvie
100MG;40MG ; Tablet
Less Than $1000 mn
None None
Less Than 5
 None
None None
MAVYRET is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult and pediatric patients 3 years and older with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). • MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
Yes
MAVYRET Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10
*** *********
****-***** ********* ****-***** ********* ****-***** ********* *********** ******* ******* *** ****** ******** ********** ****-***** ********* ****** *** ******** *** ******* *** ******** *** ******* ***** ******* ***** ***** ************** ************ *** ******** ***

MAVYRET - (50MG;20MG/PACKET ; Pellets)

GLECAPREVIR; PIBRENTASVIR Abbvie
50MG;20MG/PACKET ; Pellets
Less Than $1000 mn
None None
None None
None None
MAVYRET is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult and pediatric patients 3 years and older with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). • MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
Yes
MAVYRET Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
*** *********
****-***** ********* ****-***** ********* ****-***** ********* *********** ******* ******* *** ****** ******** ********** ****-***** ********* ****** *** ******** *** ******* ***** ******* *****

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.